For Immediate Release **Nov 2, 2023**

Dr Lal PathLabs Limited records revenue of Rs 601 Cr in Q2 FY 2023-24

New Delhi, India, Nov 2, 2023 – Dr Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2023.

Consolidated Performance Highlights: Q2 FY 2023-24 vs Q2 FY 2022-23

- Total Revenue increased by 12.6% in Q2 FY24
- Revenue excluding RTPCR increased by 14.4% in Q2 FY24
- EBITDA margin for Q2 FY24 is 29.6%
- PAT margin for Q2 FY24 is 18.4%

Financial Overview (Consolidated) in Rs Cr

Particulars	Q2			FH		
	FY24	FY23	Gr %	FY24	FY23	Gr %
Revenue	**601**	**534**	***12.6%***	**1142**	**1037**	***10.2%***
Operating Expenditure	**424**	**390**	***8.6%***	**818**	**775**	***5.6%***
EBITDA	**178**	**144**	***23.6%***	**324**	**261**	***24.0%***
Margins	*29.6%*	*26.9%*		*28.4%*	*25.2%*	
Other Income	18	9		32	17	
Depreciation Cost	36	39		71	75	
EBIT	**160**	**114**	***40.6%***	**285**	**204**	***40.2%***
Margins	*26.6%*	*21.3%*		*25.0%*	*19.6%*	
Finance Cost	8	11		16	19	
PBT	**152**	**103**	***48.0%***	**270**	**184**	***46.4%***
Margins	*25.3%*	*19.3%*		*23.6%*	*17.8%*	
PAT	**111**	**72**	***52.9%***	**194**	**131**	***48.7%***
Margins	*18.4%*	*13.6%*		*17.0%*	*12.6%*	
EPS	**13.2**	**8.6**	***52.2%***	**23.1**	**15.6**	***48.0%***

Classification: Public

About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2023 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,102 Patient Service Centers (PSCs) and 10,938 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel
Group Chief Financial Officer
Dr Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Kritika Khatwani
Adfactors PR

+91 8604801332
kritika.khatwani@adfactorspr.com

For further information on Dr Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

Classification: Public